FDA releases 14 drug rejection letters after 3-month pause
The FDA has resumed the release of drug rejection letters, issuing 14 Complete Response Letters (CRLs) following a three-month disclosure pause.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
The FDA has ended a three-month freeze on the disclosure of Complete Response Letters (CRLs), releasing 14 new drug rejection letters. This action follows a period where the agency had confirmed a pause in posting these documents.
Coverage from Endpoints News, Fierce Biotech, and BioSpace focuses on the volume of the newly released letters. Meanwhile, reports from finance.biggo.com highlight warnings from Sue Sutter and Derrick Gingery that the disclosure freeze and crackdowns on direct-to-consumer advertising are likely headed for court.
Future developments may include legal proceedings regarding the FDA's disclosure freeze and DTC advertising policies, as well as further updates on medical affairs integration and recruitment models mentioned by Applied Clinical Trials Online.
Synthesized by Archynetys from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 1h ago.
Quick answers
How many drug rejection letters did the FDA release?
The FDA released 14 new Complete Response Letters (CRLs).
How long was the pause on CRL disclosures?
The pause lasted for three months.
What other FDA actions are mentioned as potentially facing legal challenges?
A crackdown on direct-to-consumer (DTC) advertising is likely headed for court, alongside the CRL disclosure freeze.
Coverage (5)
- ACT Brief: FDA CRL Transparency Pause, Protocol-Centric Recruitment Model Shift, and Medical Affairs Integration in Development Applied Clinical Trials Online · 9h ago
- FDA's CRL Disclosure Freeze and DTC Ad Crackdown Likely Headed for Court, Sue Sutter and Derrick Gingery Warn finance.biggo.com · 9h ago
- FDA posts new rejection letters days after confirming pause BioSpace · 9h ago
- FDA returns to releasing pharma rejection letters with 14 new CRLs Endpoints News · 9h ago
- FDA releases 14 drug rejection letters after 3-month pause Fierce Biotech · 9h ago
Topics
Related trends
Popular dog food recalled nationwide may contain sharp metal fragments, FDA says
The FDA has announced a nationwide recall of a popular canned dog food brand due to potential contamination with sharp metal fragments.
Sanofi snags FDA thumbs up for Sarclisa as 1st cancer drug delivered by on-body injector
Sanofi's Sarclisa becomes the first cancer drug to receive FDA approval for delivery via an on-body injector.
FDA moves to expose hidden foreign drug factories, strengthen domestic production in sweeping rule proposal
The FDA has introduced a proposal to consolidate registration requirements for distributed drug manufacturing networks, aiming to increase supply chain transparency.
'We're paranoid.' As China biotech competition heats up, American drugmakers get more secretive
6 news sources are covering this Business story right now — Archynetys is tracking how fast it spreads.
Ozempic Face, Blindness Claims, And Billions In Potential Damages: The GLP-1 Reckoning
Public scrutiny regarding the mental, physical, and legal implications of GLP-1 receptor agonists intensifies amid reports of potential litigation.
FDA recalls eye drops over possible 'foreign substance'
6 news sources are covering this Business story right now — Archynetys is tracking how fast it spreads.